According to
a new research report “Acute
Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2019, Clinical
Trials and Results, Patents, Designations, Collaborations, and Other
Developments” published by Pharma Proff, AKI therapeutics currently exhibits a proliferating
pipeline of 39 therapeutic candidates.
AKI or acute
kidney failure is a common medical condition reported among hospitalized
patients, especially those with multiple comorbid conditions. AKI can occur due
to various reasons including decreased renal perfusion, and obstruction of the
urinary collecting system. Dehydration, abdominal pain, rise in blood pressure,
mild back pain, and vomiting are some of the symptoms associated with the
disease.
According to
the research findings, majority of pipeline drug candidates are being developed
for intravenous route administration. The advantage with this administration
includes entire administered dose reaches the systemic circulation immediately,
which increases the bioavailability of drug. Administration of therapeutics for
AKI through intravenous route has shown promising results in clinical studies.
In November
2018, Angion Biomedica Corp. and Sinovant Sciences HK Limited entered into a
collaboration and license agreement for the development of ANG-3777 for the
treatment of patients with delayed graft function (DGF) following kidney
transplantation and AKI following open-heart surgery requiring cardiopulmonary
bypass.
Similarly,
in May 2016, A1M Pharma AB collaborated with CSL Behring LLC to investigate the
potential of combination therapy of Alpha 1 Microglobulin (A1M) and plasma
protein in patients suffering from pre-eclampsia and AKI. The endogenous
protein A1M is expected to showcase several protective mechanisms in tissues.
Sentien
Biotechnologies Inc., AM-Pharma B.V., and Quark Pharmaceuticals Inc., are some
other major companies involved in the development of drug candidates for the
treatment of AKI.
AKI
Therapeutics Pipeline Analysis
By Phase
By Molecule
Type
By Route of
Administration
By Company
No comments:
Post a Comment